A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Health Technology Assessment is indexed and abstracted in NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for top...

A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial

“…In line with recommendations from a HTA-funded primary care depression trial by Peveler and colleagues, 16 GP practices were reimbursed for the additional time involved in recruitment of patients to the trial via service support costs. An additional GP practice incentive was the use of the Quality and Outcomes Framework (QOF).…”

“…We therefore powered our trial both to capture any benefit of cCBT over usual GP care alone and to test the non-inferiority of free-to-use cCBT. We based our sample size calculation on the usual care arm of our own primary care trial of collaborative care for depression, where the proportion of patients responding to usual care was in the region of 0.6; 29 a response rate similar to that found in a UK HTA trial of antidepressants in primary care 16 and a US pragmatic depression trial. 30 We regarded a response rate of not more than 0.15 below this rate as being acceptable, given the additional care options that are available to patients who do not initially respond to cCBT within a stepped care framework.…”

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

“…Six studies 139,142,144,[147][148][149] investigated the known-group validity of the EQ-5D across severity groups, five studies 129,136,137,143,145 reported convergent validity of the EQ-5D and 14 studies 50,[130][131][132][133][134][135][136][137][138]140,141,145,146 investigated the responsiveness of the EQ-5D. Two studies 139,142 had known-groups differences in the SF-6D, three 132,134,137 had convergent validity and two 136,145 had responsiveness.…”

“…In all, there were 22 studies 50, identified with data on the validity and/or responsiveness of the generic HRQoL measures in depression and anxiety for EQ-5D and SF-6D. Fourteen studies 50,129,[136][137][138][139][142][143][144][145][146][147][148][149] had data on the EQ-5D and seven 130,131,[133][134][135]140,141 contained data on the SF-6D. Studies were undertaken in at least 12 countries (a number covered Europe).…”

“The trouble with QALYs…”

“…An open, pragmatic randomised trial by Peveler et al (2005) compared three treatments for depression in primary care: a tricyclic antidepressant (TCA, choosing one of three options), a selective serotonin reuptake inhibitor (SSRI, choosing again one of three options) and lofepramine. Among the outcome indicators used was the EQ-5D, alongside more familiar depression scales.…”